Durable antitumor responses to CD47 blockade require adaptive immune stimulation

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

Therapeutic antitumor antibodies treat cancer by mobilizing both innate and adaptive immunity. CD47 is an antiphagocytic ligand exploited by tumor cells to blunt antibody effector functions by transmitting an inhibitory signal through its receptor signal regulatory protein alpha (SIRPα). Interferenc...

Full description

Bibliographic Details
Main Authors: Sockolosky, Jonathan T. (Author), Ho, Chia Chi M. (Author), Almo, Steven C. (Author), Garcia, K. Christopher (Author), Dougan, Michael (Contributor), Kauke, Monique Jacqueline (Contributor), Ploegh, Hidde (Contributor), Ingram, Jessica R. (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Whitehead Institute for Biomedical Research (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: National Academy of Sciences (U.S.), 2016-12-02T20:15:13Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items